A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04647487 |
|
Recruitment Status :
Not yet recruiting
First Posted : December 1, 2020
Last Update Posted : February 21, 2021
|
Sponsor:
Eli Lilly and Company
Information provided by (Responsible Party):
Eli Lilly and Company
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Breast Cancer | Drug: LY3484356 | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Basic Science |
| Official Title: | EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer |
| Estimated Study Start Date : | February 8, 2021 |
| Estimated Primary Completion Date : | March 21, 2022 |
| Estimated Study Completion Date : | March 21, 2022 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Breast cancer
MedlinePlus related topics:
Breast Cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: LY3484356 Dose Level 1
Administered orally.
|
Drug: LY3484356
Administered orally. |
|
Experimental: LY3484356 Dose Level 2
Administered orally.
|
Drug: LY3484356
Administered orally. |
Primary Outcome Measures :
- Change from Baseline in ER Expression [ Time Frame: Baseline, Day 15 ]ER expression measured by H-score immunohistochemistry (IHC)
Secondary Outcome Measures :
- Change from Baseline in Ki-67 Index [ Time Frame: Baseline, Day 15 ]Ki-67 index measured by percentage positive scoring by IHC
- Change from Baseline in Progesterone Receptor (PR) Expression [ Time Frame: Baseline, Day 15 ]PR expression measured by H-score IHC
- PK: Plasma Concentration of LY3484356 [ Time Frame: Baseline through follow-up at Day 15 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Participant Must:
- Have histologically confirmed invasive ER+, HER2- breast carcinoma
- Be willing and able to provide pre- and on-treatment tumor samples
- Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale
- Have adequate organ function
- Be able to swallow capsules
Exclusion Criteria:
Participant Must Not:
- Have bilateral invasive breast cancer
- Have metastatic breast cancer
- Plan to receive concurrent neoadjuvant therapy with any other non-protocol anti-cancer therapy
- Have had prior therapy (of any kind) for an invasive or non-invasive breast cancer
- Have had prior radiotherapy to the ipsilateral chest wall for any malignancy
- Have had prior anti-estrogen therapy with raloxifene, tamoxifen, aromatase inhibitor, or other selective estrogen receptor modulator (SERM), either for osteoporosis or prevention of breast cancer
- Have had prior hormone-replacement therapy within 4 weeks of the start of study treatment
- Have had major surgery within 28 days prior to randomization to allow for post-operative healing of the surgical wound and site(s)
- Be pregnant or breastfeeding
- Have certain infections such as hepatitis or tuberculosis or HIV that are not well controlled
- Have another serious medical condition
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04647487
Contacts
| Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or | 1-317-615-4559 | ClinicalTrials.gov@lilly.com |
Locations
Show 22 study locations
Sponsors and Collaborators
Eli Lilly and Company
Investigators
| Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Additional Information:
| Responsible Party: | Eli Lilly and Company |
| ClinicalTrials.gov Identifier: | NCT04647487 |
| Other Study ID Numbers: |
17575 J2J-MC-JZLB ( Other Identifier: Eli Lilly and Company ) 2020-002810-42 ( EudraCT Number ) |
| First Posted: | December 1, 2020 Key Record Dates |
| Last Update Posted: | February 21, 2021 |
| Last Verified: | February 15, 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Eli Lilly and Company:
|
SERD |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |